Seelos Therapeutics (SEEL)
(Delayed Data from NSDQ)
$1.20 USD
-0.02 (-1.64%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.18 -0.02 (-1.67%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Seelos Therapeutics, Inc. [SEEL]
Reports for Purchase
Showing records 21 - 40 ( 65 total )
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Bolsters Cash Level Ahead of Eventful 1H21, Encouraging Recent Deal Comps
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
3Q20: New Report Supports Ketamine as Antisuicidal, SLS-007 Patent Issued
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Signs Preclinical SLS-004 Sponsored Research Agreement with Duke U for PD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Small Price to Pay for a Company About to Begin Two Pivotal Programs
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
We are transferring coverage with a Buy rating and a $12 target price
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Checklist for What SLS-002 Needs to Show Going Forward
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Checklist for What SLS-002 Needs to Show Going Forward
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
1Q20 - Potential PRV Increases Profile of SLS-005 Program
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Six Reasons Why You Need Look at SLS-002 This May
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y